Patents by Inventor Markus Ostermeier

Markus Ostermeier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210009588
    Abstract: The present invention encompasses compounds of formula (1) wherein the groups R1 to R4, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: September 24, 2020
    Publication date: January 14, 2021
    Inventors: Juergen RAMHARTER, Christiane KOFINK, Heinz STADTMUELLER, Tobias WUNBERG, Marco Hans HOFMANN, Anke BAUM, Michael GMACHL, Dorothea Ingrid RUDOLPH, Fabio SAVARESE, Markus OSTERMEIER, Markus FRANK, Annika GILLE, Stefan GOEPPER, Marco SANTAGOSTINO, Julian WIPPICH
  • Publication number: 20200276197
    Abstract: The invention provides a salt of a tetrahydropyranylmethylaminopyrimidine amide, such as the citrate salt of (4-((3R,4R)-3-methoxytetrahydropyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone, pharmaceutical compositions containing the same, processes for preparing the same, and methods of medical treatment using the same.
    Type: Application
    Filed: February 11, 2020
    Publication date: September 3, 2020
    Inventors: Markus Ostermeier, Ulrike Werthmann
  • Patent number: 10568885
    Abstract: The invention provides a salt of a tetrahydropyranylmethylaminopyrimidine amide, such as the citrate salt of (4-((3R,4R)-3-methoxytetrahydropyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone, pharmaceutical compositions containing the same, processes for preparing the same, and methods of medical treatment using the same.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: February 25, 2020
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Markus Ostermeier, Ulrike Werthmann
  • Publication number: 20200024261
    Abstract: The present invention relates to difluoromethyl-phenyl triazoles of general formula (I) which are modulators of GABAA receptors containing the ?5 subunit, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: July 19, 2019
    Publication date: January 23, 2020
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Janus Schreiber Larsen, Florian Binder, Yunhai Cui, Oliver Hucke, Radoslaw Lipinski, Florian Montel, Markus Ostermeier, Alexandre Perera, Stefan Peters
  • Patent number: 10525536
    Abstract: A tool for roughening a borehole surface. The tool includes a coupling portion for clamping the tool in a drilling machine; and a tool head for machining the borehole surface, where the tool head comprises a cutter that is circumferentially disposed on the tool head, and where the tool head has at least one slit, which passes through from one side to the other and which, starting from an end face of the tool head, and extends axially along a longitudinal axis of the tool.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: January 7, 2020
    Assignee: Hilti Aktiengesellschaft
    Inventors: Hans-Peter Lederle, Markus Renner, Rainer Strobel-Schmidt, Franz Popp, Peter Ostermeier
  • Publication number: 20190262339
    Abstract: The invention provides a salt of a tetrahydropyranylmethylaminopyrimidine amide, such as the citrate salt of (4-((3R,4R)-3-methoxytetrahydropyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone, pharmaceutical compositions containing the same, processes for preparing the same, and methods of medical treatment using the same.
    Type: Application
    Filed: December 19, 2018
    Publication date: August 29, 2019
    Inventors: Markus Ostermeier, Ulrike Werthmann
  • Publication number: 20190194192
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: December 20, 2018
    Publication date: June 27, 2019
    Inventors: Juergen RAMHARTER, Christiane KOFINK, Heinz STADTMUELLER, Tobias WUNBERG, Marco Hans HOFMANN, Anke BAUM, Michael GMACHL, Dorothea Ingrid RUDOLPH, Fabio SAVARESE, Markus OSTERMEIER, Markus FRANK, Annika GILLE, Stefan GOEPPER, Marco SANTAGOSTINO, Julian WIPPICH
  • Patent number: 10213428
    Abstract: The invention provides a salt of a tetrahydropyranylmethylaminopyrimidine amide, such as the citrate salt of (4-((3R,4R)-3-methoxytetrahydropyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone, pharmaceutical compositions containing the same, processes for preparing the same, and methods of medical treatment using the same.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: February 26, 2019
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Markus Ostermeier, Ulrike Werthmann
  • Publication number: 20180207157
    Abstract: The invention provides a salt of a tetrahydropyranylmethylaminopyrimidine amide, such as the citrate salt of (4-((3R,4R)-3-methoxytetrahydropyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyetetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone, pharmaceutical compositions containing the same, processes for preparing the same, and methods of medical treatment using the same.
    Type: Application
    Filed: December 21, 2017
    Publication date: July 26, 2018
    Inventors: Markus Ostermeier, Ulrike Werthmann
  • Patent number: 9309228
    Abstract: The present invention relates to a compound of formula (I), which has valuable pharmacological properties, particularly an inhibiting effect on signal transduction mediated by tyrosine kinases, processes for stereoselectively preparing these compounds, particularly pharmaceutical formulations suitable for inhalation and their use for the treatment of diseases, particularly tumoral diseases, benign prostatic hyperplasia and diseases of the lungs and airways.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: April 12, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Markus Ostermeier, Peter Sieger
  • Patent number: 9212120
    Abstract: Disclosed is a method for the synthesis of spiro[2.5]octane-5,7-dione useful as intermediate in the manufacture of pharmaceutically active ingredients. Also disclosed are novel intermediates used in the synthesis of this compound.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: December 15, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Torsten Busch, Sven Anklam, Joerg Jung, Markus Ostermeier
  • Patent number: 8993753
    Abstract: The present invention relates to a process for the stereoselective preparation of compounds of formulae (1A) and (1B) and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for the treatment of diseases, particularly tumoral diseases as well as benign prostatic hyperplasia (BPH), diseases of the lungs and airways.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: March 31, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Markus Ostermeier, Juergen Daeubler, Guenther Huchler, Stephan Kling, Marco Santagostino
  • Publication number: 20140371226
    Abstract: The present invention relates to a compound of formula (I), which has valuable pharmacological properties, particularly an inhibiting effect on signal transduction mediated by tyrosine kinases, processes for stereoselectively preparing these compounds, particularly pharmaceutical formulations suitable for inhalation and their use for the treatment of diseases, particularly tumoral diseases, benign prostatic hyperplasia and diseases of the lungs and airways.
    Type: Application
    Filed: August 28, 2014
    Publication date: December 18, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Waldemar PFRENGLE, Guenther HUCHLER, Markus OSTERMEIER, Peter SIEGER
  • Patent number: 8906931
    Abstract: The present invention relates to a compound of formula (I), which has valuable pharmacological properties, particularly an inhibiting effect on signal transduction mediated by tyrosine kinases, processes for stereoselectively preparing these compounds, particularly pharmaceutical formulations suitable for inhalation and their use for the treatment of diseases, particularly tumoral diseases, benign prostatic hyperplasia and diseases of the lungs and airways.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: December 9, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Waldemar Pfrengle, Guenther Huchler, Markus Ostermeier, Peter Sieger
  • Publication number: 20140336405
    Abstract: Disclosed is a method for the synthesis of spiro[2.5]octane-5,7-dione useful as intermediate in the manufacture of pharmaceutically active ingredients. Also disclosed are novel intermediates used in the synthesis of this compound.
    Type: Application
    Filed: July 29, 2014
    Publication date: November 13, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Torsten BUSCH, Sven ANKLAM, Joerg JUNG, Markus OSTERMEIER
  • Patent number: 8853225
    Abstract: The present invention relates to a compound of formula (I), which has valuable pharmacological properties, particularly an inhibiting effect on signal transduction mediated by tyrosine kinases, processes for stereoselectively preparing these compounds, particularly pharmaceutical formulations suitable for inhalation and their use for the treatment of diseases, particularly tumoral diseases, benign prostatic hyperplasia and diseases of the lungs and airways.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: October 7, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Waldermar Pfrengle, Guenther Huchler, Markus Ostermeier, Peter Sieger
  • Publication number: 20140135495
    Abstract: The present invention relates to a process for the stereoselective preparation of compounds of formulae (1A) and (1B) and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for the treatment of diseases, particularly tumoral diseases as well as benign prostatic hyperplasia (BPH), diseases of the lungs and airways.
    Type: Application
    Filed: January 14, 2014
    Publication date: May 15, 2014
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Markus OSTERMEIER, Juergen DAEUBLER, Guenther HUCHLER, Stephan KLING, Marco SANTAGOSTINO
  • Patent number: 8658790
    Abstract: The present invention relates to a process for the stereoselective preparation of compounds of formulae (1A) and (1B) and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for the treatment of diseases, particularly tumoral diseases as well as benign prostatic hyperplasia (BPH), diseases of the lungs and airways.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: February 25, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Markus Ostermeier, Juergen Daeubler, Guenther Huchler, Stephan Kling, Marco Santagostino
  • Publication number: 20140039203
    Abstract: Disclosed is a method for the synthesis of spiro[2.5]octane-5,7-dione useful as intermediate in the manufacture of pharmaceutically active ingredients. Also disclosed are novel intermediates used in the synthesis of this compound.
    Type: Application
    Filed: August 1, 2013
    Publication date: February 6, 2014
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Torsten BUSCH, Sven ANKLAM, Joerg JUNG, Markus OSTERMEIER
  • Publication number: 20140024628
    Abstract: The present invention relates to a compound of formula (I), which has valuable pharmacological properties, particularly an inhibiting effect on signal transduction mediated by tyrosine kinases, processes for stereoselectively preparing these compounds, particularly pharmaceutical formulations suitable for inhalation and their use for the treatment of diseases, particularly tumoral diseases, benign prostatic hyperplasia and diseases of the lungs and airways.
    Type: Application
    Filed: July 17, 2013
    Publication date: January 23, 2014
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Markus OSTERMEIER, Peter SIEGER